A quarter of people seeking care for symptoms of chronic respiratory diseases in Kenya may incur "catastrophic" health costs, ...

Digital inhalers that allow remote patient monitoring may predict impending exacerbations, or episodes when symptoms of COPD ...

Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.

Emphysema is a slow killer. Severe emphysema even alienates family members as the patients relegate themselves to the length of their oxygen tubing and suffer through an acquired mutism from ...

Chronic obstructive pulmonary disease (COPD) affects 25 million people in the U.S. and is the fifth leading cause of death ...

COPD has a large economic impact on the healthcare system and a destructive impact on the lives of patients and their ...

Chronic obstructive pulmonary disease (COPD) is a complex disease in which neutrophils play a central role. However, there are many different interactions with endothelial and pulmonary cells as ...

Learn about COPD medications, including bronchodilators, steroids, and combination treatments. Understand how they work, their side effects, and ways to manage COPD effectively.

Research on the Digihaler highlights its potential to track COPD inhaler use, offering real-world data to improve treatment ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial.

Researchers discover an unusual accumulation of particles in people with the disease; the causes are still unclear.

The CEO of Connect Biopharma discusses the unique challenges that patients with asthma and COPD face. Pharmaceutical Executive: What drew you to Connect Biopharma?